ARWR

Arrowhead Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

16.420

+0.36(2.242%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

16.480

Open

15.550

VWAP

15.95

Vol

2.81M

Mkt Cap

2.27B

Low

15.010

Amount

44.75M

EV/EBITDA(TTM)

Total Shares

124.20M

1.56B

EV/OCF(TTM)

23.42

P/S(TTM)

3.66

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.401

-70.72%

-0.666

-52.09%

-1.224

-144.51%

Estimates Revision

The market is revising Upward the revenue expectations for Arrowhead Pharmaceuticals, Inc. (ARWR) for FY2025, with the revenue forecasts being adjusted by 98.19% over the past three months. During the same period, the stock price has changed by 26.02%.

Revenue Estimates for FY2025

Revise Upward

+98.19%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-94.1%

In Past 3 Month

Stock Price

Go Up

+26.02%

In Past 3 Month

12 Analyst Rating

152.38% Upside

Wall Street analysts forecast ARWR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 41.44 USD with a low forecast of 17.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

4 Hold

0 Sell

Moderate Buy

152.38% Upside

Current: 16.420

Low

17.00

Averages

41.44

High

80.00

152.38% Upside

Current: 16.420

Low

17.00

Averages

41.44

High

80.00

UBS

Buy

downgrade

$71 -> $63

2025-05-14

Reason

UBS

Price Target

$71 -> $63

2025-05-14

downgrade

Buy

Reason

UBS lowered the firm's price target on Arrowhead to $63 from $71 and keeps a Buy rating on the shares.

Citi

Neutral

downgrade

$21 -> $17

2025-05-13

Reason

Citi

Price Target

$21 -> $17

2025-05-13

downgrade

Neutral

Reason

Citi lowered the firm's price target on Arrowhead to $17 from $21 and keeps a Neutral rating on the shares. The company reported fiscal Q2 financial results and gave progress updates on its "extensive" pipeline of over 15 assets in development, the analyst tells investors in a research note. The firm says that while the decision to pay down some of its credit facility will be seen positively by some investors, it still sees a "low ceiling for shares" in the short term due to limited upside for the familial chylomicronemia syndrome launch.

B. Riley Securities

Mayank Mamtani

Strong Buy

Reiterates

$51 → $38

2025-02-14

Reason

B. Riley Securities

Mayank Mamtani

Price Target

$51 → $38

2025-02-14

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$80

2025-02-12

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$80

2025-02-12

Reiterates

Strong Buy

Reason

Chardan Capital

Keay Nakae

Strong Buy

Maintains

$60

2025-02-11

Reason

Chardan Capital

Keay Nakae

Price Target

$60

2025-02-11

Maintains

Strong Buy

Reason

RBC Capital

Luca Issi

Buy

Reiterates

$42

2025-02-11

Reason

RBC Capital

Luca Issi

Price Target

$42

2025-02-11

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Arrowhead Pharmaceuticals Inc (ARWR.O) is -5.00, compared to its 5-year average forward P/E of -29.19. For a more detailed relative valuation and DCF analysis to assess Arrowhead Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-29.19

Current PE

-5.00

Overvalued PE

4.49

Undervalued PE

-62.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-30.70

Current EV/EBITDA

-9.46

Overvalued EV/EBITDA

5.82

Undervalued EV/EBITDA

-67.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

26.07

Current PS

7.46

Overvalued PS

39.73

Undervalued PS

12.40

Financials

Annual

Quarterly

FY2025Q3

27.77M

Total Revenue

FY2025Q3

YoY :

-6.01%

-165.55M

Operating Profit

FY2025Q3

YoY :

+2.69%

-178.65M

Net Income after Tax

FY2025Q3

YoY :

-8.70%

-1.26

EPS - Diluted

FY2025Q3

YoY :

+20.96%

-157.08M

Free Cash Flow

FY2025Q3

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q3

YoY :

-99.89%

-3.08

FCF Margin - %

FY2025Q3

YoY :

-94.76%

-643.40

Net Margin - %

FY2025Q3

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

7.6M

USD

6-9

Months

3.9M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

917.4K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

22.2K

Volume

Months

6-9

3.8M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

7.6M

USD

6-9

Months

3.9M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ARWR News & Events

Events Timeline

2025-08-07 (ET)

2025-08-07

16:06:11

Arrowhead reports Q3 EPS ($1.26), consensus ($1.10)

2025-08-01 (ET)

2025-08-01

06:50:37

Arrowhead announces asset purchase agreement between Sanofi, Visirna

2025-07-28 (ET)

2025-07-28

12:02:53

Sarepta tells Bloomberg expects to honor Arrowhead commitments

News

8.5

08-01Newsfilter

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

8.5

08-01SeekingAlpha

Arrowhead unit sells rights for plozasiran to Sanofi in Greater China

9.0

07-29Benzinga

Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On?

People Also Watch

Minerals Technologies Inc

ICF International Inc

FAQ

What is Arrowhead Pharmaceuticals Inc (ARWR) stock price today?

The current price of ARWR is 16.42 USD — it has increased 2.24 % in the last trading day.

ARWR

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ARWR News & Events

Events Timeline

News

People Also Watch

FAQ

What is Arrowhead Pharmaceuticals Inc (ARWR) stock price today?

What is Arrowhead Pharmaceuticals Inc (ARWR)'s business?

What is the price predicton of ARWR Stock?

What is Arrowhead Pharmaceuticals Inc (ARWR)'s revenue for the last quarter?

What is Arrowhead Pharmaceuticals Inc (ARWR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Arrowhead Pharmaceuticals Inc (ARWR)'s fundamentals?

How many employees does Arrowhead Pharmaceuticals Inc (ARWR). have?

What is Arrowhead Pharmaceuticals Inc (ARWR) market cap?